Zobrazeno 1 - 10
of 247
pro vyhledávání: '"K. M. Abdulkadyrov"'
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 22-28 (2022)
In this article mechanisms of anaemia development in patients with lymphatic tissue malignant diseases are presented. Therapy efficacy of erythropoiesis-stimulating agents (EPO) in patients with lymphoproliferative disorders and anaemia (n = 21) is s
Externí odkaz:
https://doaj.org/article/0e4ef83caabe4f74bd9265350f9824e9
Autor:
S. S. Bessmeltsev, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 73-78 (2022)
The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second
Externí odkaz:
https://doaj.org/article/39b34bd8208c4ebdadaab5e49b0816d9
Autor:
A. A. Maschan, A. G. Rumyantsev, L. G. Kovaleva, B. V. Afanasiev, T. I. Pospelova, A. Yu. Zaritskiy, K. M. Abdulkadyrov, V. V. Ptushkin, N. V. Tsvetaeva, I. A. Lisukov, G. N. Salogub, A. K. Golenkov, N. V. Medvedeva, O. A. Rukavitsyn, V. L. Ivanova, I. V. Markova
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 36-45 (2022)
New guidelines on diagnosis and treatment of a primary immune thrombocytopenia (ITP) in children and adults, on the basis of modern pathogenesis conceptions and considering possibilities of hematological practice in Russia are presented. Guidelines a
Externí odkaz:
https://doaj.org/article/6220b641931849d780f5e030ba86106b
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 61-66 (2022)
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a me
Externí odkaz:
https://doaj.org/article/8553a7bdc296417c8a2e1b3fa806ced5
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 40-45 (2022)
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 6
Externí odkaz:
https://doaj.org/article/b683f210247445cdb987afa77e18fa09
Autor:
S. S. Bessmeltsev, E. V. Karyagina, L. V Stelmashenko, N. V. Stepanova, E. R. Machulaiten, G. N. Salogub, I. A. Skorokhod, N. V. Medvedeva, E. I. Podoltseva, L. M. Matyukhina, A. S. Nizamutdinova, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 52-62 (2022)
The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patie
Externí odkaz:
https://doaj.org/article/d13b8f52d7bd41c4a2309ca155e24f5c
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 6-13 (2022)
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate
Externí odkaz:
https://doaj.org/article/c2efdc3ba2154cfb809d445aa9adf43d
Autor:
A. A. Zhernyakova, I. S. Martynkevich, V. A. Shuvaev, L. B. Polushkina, M. S. Fominykh, V. Yu. Udal’eva, I. I. Zotova, D. I. Shiсhbabaeva, S. V. Voloshin, S. S. Бессмельцев, A. V. Chechetkin, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 12, Iss 2, Pp 30-38 (2017)
Background. Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence (JAK2V617F (JAK2+), MPL (MPL+
Externí odkaz:
https://doaj.org/article/ff4d08c63d6c4263aec7f738cf2269b0
Publikováno v:
Онкогематология, Vol 11, Iss 1, Pp 24-33 (2016)
The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patien
Externí odkaz:
https://doaj.org/article/a280610f085d4557a6f25ecb8e03bb26
Publikováno v:
Онкогематология, Vol 10, Iss 3, Pp 28-42 (2015)
The literature review and own long-term polycythemia vera diagnosis and treatment experience are presented in this article. The results of newest advances in pathogenesis description, modern diagnostic techniques and treatment modalities in polycythe
Externí odkaz:
https://doaj.org/article/2e6c7e6963804fa4b06f4b771ace49aa